Italia markets close in 3 hours 47 minutes

Nova Ltd. (0YAA.L)

LSE - LSE Prezzo differito. Valuta in ILS.
Aggiungi a watchlist
357,77+0,47 (+0,13%)
Al 04:52PM BST. Mercato aperto.
Schermo intero
Chiusura precedente357,30
Aperto357,77
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno357,77 - 357,77
Intervallo di 52 settimane357,77 - 357,77
Volume31
Media VolumeN/D
Capitalizzazione1,003M
Beta (5 anni mensile)1,27
Rapporto PE (ttm)0,99
EPS (ttm)3,60
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

    Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV – a subtype of AMD, prevalent among Asian populations with high unmet medical need MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea L

  • GlobeNewswire

    Opthea To Present at SVB Leerink Global Healthcare Conference

    MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. The presentation will be available beginning Thursday, February 1

  • GlobeNewswire

    Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

    MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022. Professor Gemmy Cheung will present data from patients with polypoidal choroidal vasculo